BankPlus Trust Department Boosts Stock Holdings in Edwards Lifesciences Corporation $EW

BankPlus Trust Department boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,907 shares of the medical research company’s stock after buying an additional 391 shares during the period. BankPlus Trust Department’s holdings in Edwards Lifesciences were worth $931,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Arlington Trust Co LLC increased its stake in Edwards Lifesciences by 1.2% during the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after buying an additional 135 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after buying an additional 142 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares during the last quarter. Dakota Wealth Management boosted its stake in Edwards Lifesciences by 2.5% during the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after buying an additional 146 shares during the last quarter. Finally, Leo Wealth LLC boosted its stake in Edwards Lifesciences by 1.2% during the first quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after buying an additional 150 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Trading Up 0.2%

EW opened at $76.70 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $64.51 and a 52 week high of $83.00. The business has a fifty day simple moving average of $78.39 and a 200-day simple moving average of $76.05. The firm has a market cap of $45.03 billion, a P/E ratio of 11.04, a P/E/G ratio of 3.68 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business posted $0.70 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.